Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). Although Src TK has been involved in such resistance, clinical development of its inhibitors has bee...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Formisano, Luigi, D'Amato, Valentina, Servetto, Alberto, Brillante, Simona, Raimondo, Lucia, Di Mauro, Concetta, Marciano, Roberta, Orsini, Roberta Clara, Cosconati, Sandro, Randazzo, Antonio, Parsons, Sarah J., Montuori, Nunzia, Veneziani, Bianca Maria, De Placido, Sabino, Rosa, Roberta, Bianco, Roberto
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2015
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694888/
https://ncbi.nlm.nih.gov/pubmed/26325669
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg